The FDA is reviewing an Alzheimer's treatment and is expected to announce its decision in July. The Leqembi treatment showed a 27-percent slow in disease progression in clinical trials. But it also has side effects that could include brain swelling and bleeding and costs over 26-thousand dollars a year